Literature DB >> 8671619

Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo.

G F Hoyne1, B A Askonas, C Hetzel, W R Thomas, J R Lamb.   

Abstract

We have previously demonstrated that intranasal (i.n.) administration of an immunodominant peptide (p1-111-139) derived from the house dust mite (HDM) allergen Der p 1 inhibits antigen-specific CD4+ T cell responses in H-2b mice. Here we report that i.n. peptide induced a rapid but transient activation of MHC class II restricted CD4+ T cells that peaked 4 days after peptide treatment and was of similar magnitude to that induced by parenteral immunization with antigen in adjuvant. During the early phase of the response lymph node and splenic T cells secreted a range of lymphokines when re-stimulated in vitro with p1 111-139; however, by day 14 IL-2 and IFN-gamma secretion by T cells were down-regulated. Mice deficient in CD8+ T cells became tolerant by i.n. treatment with peptide, suggesting that CD8+ T cells are not involved in down-regulating the CD4+ T cell response. Rechallenging mice with a single dose of p1 111-139 21 days after the initial treatment elicited a further transient T cell response, which was subsequently down-regulated over time. Although the i.n. peptide induced a strong transient CD4+ T cell response, only low levels of peptide-specific antibodies were detected either after the initial or subsequent i.n. exposures to p1 111-139. Our findings address the mechanisms underlying peripheral T cell tolerance following i.n. administration of a high dose of immunogenic peptide and have implications for understanding the consequences of peptide immunothearapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8671619     DOI: 10.1093/intimm/8.3.335

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  34 in total

Review 1.  T-cell regulation of peripheral tolerance and immunity: the potential role for Notch signalling.

Authors:  G F Hoyne; M J Dallman; J R Lamb
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

2.  Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy.

Authors:  A D Dick; V Sharma; J Liversidge
Journal:  Br J Ophthalmol       Date:  2001-08       Impact factor: 4.638

Review 3.  The potential of peptide immunotherapy in allergy and asthma.

Authors:  F Runa Ali; A Barry Kay; Mark Larché
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 4.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 5.  Inhibition of human T-cell responses by allergen peptides.

Authors:  M Larché
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

6.  Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice.

Authors:  C Aspord; C Thivolet
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

7.  Mucosal tolerance is associated with, but independent of, up-regulation Th2 responses.

Authors:  D A Wolvers; M J van der Cammen; G Kraal
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

8.  A rice-based edible vaccine expressing multiple T cell epitopes induces oral tolerance for inhibition of Th2-mediated IgE responses.

Authors:  Hidenori Takagi; Takachika Hiroi; Lijun Yang; Yoshifumi Tada; Yoshikazu Yuki; Kaoru Takamura; Ryotaro Ishimitsu; Hideyuki Kawauchi; Hiroshi Kiyono; Fumio Takaiwa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-08       Impact factor: 11.205

Review 9.  Strategies of mucosal immunotherapy for allergic diseases.

Authors:  Yi-Ling Ye; Ya-Hui Chuang; Bor-Luen Chiang
Journal:  Cell Mol Immunol       Date:  2011-06-13       Impact factor: 11.530

Review 10.  Allergen immunotherapy with cat allergen peptides.

Authors:  A Barry Kay; Mark Larché
Journal:  Springer Semin Immunopathol       Date:  2003-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.